Kornimate/medical-research-clean huggingface dataset:
bronchoscopy anesthesia and neuropsychological assessment in children (banach) study

Conditions: Pneumonia; Atelectasis; Cough

Summary: fiberoptic bronchoscopy plays a very important role in the diagnosis and treatment of respiratory diseases in children.in china,this procedure is mainly performed under two different anesthesia methods：sedation and general anesthesia(ga) . which is better ? there are still a lot of controversies . several early retrospective studies suggest that, in addition to the possible increase in costs, general anesthesia in intraoperative complications, postoperative recovery and other aspects did not bring significant improvement. but clinically we observed that children under sedation often can not cooperate, they often shows anxiety,restless,crying,and so on, under these situation, some restraint measures may be used, which may have an impact on the child's neuropsychological development. therefore ,we design this study ,aiming to compare the influence between sedation and general anesthesia (ga) on children 's neuropsychological development.


Eligibility criteria:
inclusion criteria: * age 4-10 years * american society of anesthesiologists(asa) gradeⅰ～ⅱ * plan to accept fiberoptic bronchoscopy treatment * lives in the city where the research unit is located * signed informed consent exclusion criteria: * preterm infants less than 28 weeks of gestational age or preoperative screening found that development, cognitive or behavioral abnormalities * known congenital malformations may have a potential impact on the development of children's neuropsychological function * known to have central nervous system disorders or meet the diagnostic criteria of diagnostic and statistical manual(dsm) mental illness * children with contraindications to intravenous general anesthesia

Keywords: fiberoptic bronchoscopy neuropsychological development general anesthesia
strategies for catheter ablation of persistent atrial fibrlllation

Conditions: Atrial Fibrillation

Summary: the objective of this study is to compare the efficacy of three different ablation strategies in patients with persistent af: 1. pv antral isolation alone (pvai) 2. pv antral isolation plus ablation of drivers (pvai+drivers) 3. pv antral isolation plus isolation of posterior wall (pvai+box) all three strategies will employ contemporary catheter ablation technology using more efficient open irrigated tip cooling and contact force sensing.


Eligibility criteria:
inclusion criteria: 1. patients 18 years of age or older 2. patients undergoing first-time ablation procedure for af 3. patients with persistent af defined as a sustained episode more than 3 months but less than three years 4. patients with symptomatic af - symptomatic patients are those who have been aware of their af at any time within the last 5 years prior to enrolment. symptoms may include, but are not restricted to, palpitations, shortness of breath, chest pain, fatigue, left ventricular dysfunction, or other symptoms or any combination of the above 5. patients whose af has been refractory to at least one antiarrhythmic drug 6. at least one episode of af must have been documented by ecg, holter, loop recorder, telemetry, trans-telephonic monitor or implanted device within the last 2 years from enrolment 7. patients must be able and willing to provide written informed consent to participate in the study exclusion criteria: 1. patients with paroxysmal af (no episodes lasting \> 7 days) 2. patients with early persistent af, sustained episode ≤ 3 months 3. patients with very long lasting persistent af (episodes lasting \> 3 years) 4. patients with cha2ds2-vasc score of 0. 5. patients for whom cardioversion or sinus rhythm will never be attempted/pursued 6. patients with af felt to be secondary to an obvious reversible cause 7. patients with contraindication to oral anticoagulation or systemic anticoagulation with heparin 8. patients with left atrial diameter \> 60 mm in the parasternal long axis view 9. patients who are pregnant

Keywords: ablation
study of the intermediate metabolism in children with acute lymphoblastic leukemia (all)

Conditions: Acute Lymphoblastic Leukemia, Pediatric; Metabolism Disorder

Summary: study of the intermediate metabolism in children diagnosed with all compared to healthy matched controls.

the primary cause of this study is to investigate the changes that all may cause to the metabolome of pediatric patients, in order to better understand its mechanism of action and target metabolic pathways for potential therapies.

Eligibility criteria:
* sex: all * minimum age: 1 year * maximum age: 16 years * the study accepts healthy volunteers as matched controls for the patinets. * inclusion criteria: 1)children diagnosed with all 2) diagnosis confirmed with bone marrow biopsy 3) sampling before the initiation of therapy 4) informed consent signed * exclusion criteria: 1) children with a known chronic illness before all diagnosis 2) all remission 3) not signed informed consent * population description: patients are recruited from the pediatric hematology/oncology department of aristotle university of thessaloniki (ahepa hospital) and from the pediatric hematology/ oncology department of ippokration hospital, that host all children diagnosed with all in nothern greece. matched controls are recruited from outpatient clinic of the 2nd and 4th pediatric department of aristotle university of thessaloniki. * sampling method: non-probability sample
dose escalation of bivatuzumab mertansine in patients with advanced squamous cell carcinoma of the head and neck or esophagus

Conditions: Carcinoma, Squamous Cell

Summary: maximum tolerated dose (mtd), safety, pharmacokinetics, efficacy of bivatuzumab mertansine


Eligibility criteria:
inclusion criteria: 1. patients from 18 to 80 years of age (both inclusive) 2. patients with histologically confirmed squamous cell carcinoma of the head and neck or esophagus 3. patients with local and / or regional recurrent disease or distant metastases who are refractory to or not amenable to established treatments 4. evaluable tumour deposits 5. life expectancy of at least 3 months 6. eastern cooperative oncology group (ecog) performance score ≤ 2 7. patients must have given written informed consent (which must be consistent with international conference on harmonisation-good clinical practice (ich-gcp) and local legislation) exclusion criteria: 1. hypersensitivity to humanised or murine antibodies, immunoconjugates or the excipients of the trial drugs 2. known secondary malignancy requiring therapy 3. active infectious disease 4. brain metastases requiring therapy 5. neuropathy grade 2 or above 6. absolute neutrophil count less than 1,500/mm3 7. platelet count less than 100,000/mm3 8. bilirubin greater than 1.5 mg/dl (\> 26 μmol/l, système internationale (si) unit equivalent) 9. aspartate amino transferase (ast) and/or alanine amino transferase (alt) greater than 3 times the upper limit of normal 10. serum creatinine greater than 1.5 mg/dl (\> 132 μmol/l, si unit equivalent) 11. concomitant non-oncological diseases which are considered relevant for the evaluation of the safety of the trial drug 12. chemo-, radio- or immunotherapy within the past four weeks prior to treatment with the trial drug or during the trial (except for present trial drug) 13. men and women who are sexually active and unwilling to use a medically acceptable method of contraception 14. pregnancy or lactation 15. treatment with other investigational drugs or participation in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial (except for present trial drug) 16. patients unable to comply with the protocol
effect of a lactobacillus strain on the prevention of recurrent vaginal candidiasis

Conditions: Recurrent Vulvovaginal Candidiasis

Summary: the objective of this study is to evaluate the efficacy of the consumption of the one probiotic strain in the prevention of new vaginal candidiasis events in women with recurrent vaginal candidiasis. this is a preliminary study whose purpose is to know if this probiotic is effective in reducing the number of candidiasis events and / or increasing the time between possible relapses in women diagnosed with rvvc.

previous studies have demonstrated the effectiveness of certain probiotic strains in the treatment of vaginal candidiasis, alone or as an adjunct to antifungal treatments, as well as the effectiveness of a lactobacillus strain as maintenance treatment after antifungal treatment to reduce the recurrence rate of candidiasis however, to date, no studies have evaluated the oral efficacy of a probiotic strain of lactobacillus originally isolated from breast milk in the prevention of new vaginal yeast events in women with recurrent vaginal yeast infections. the objective of this study is to evaluate the efficacy of the consumption of the one probiotic strain in the prevention of new vaginal candidiasis events in women with recurrent vaginal candidiasis. this is a preliminary study whose purpose is to know if this probiotic is effective in reducing the number of candidiasis events and / or increasing the time between possible relapses in women diagnosed with rvvc.

Eligibility criteria:
inclusion criteria: 1. healthy women from 18 to 49 years old. 2. having suffered at least four outbreaks of vaginal yeast infection in the last year. 3. signed informed consent form. 4. agree to provide the scheduled samples. 5. agree to perform gynecological examinations 6. agree to report candidiasis events that occur during the study. 7. ability to complete surveys. exclusion criteria: 1. being currently consuming or having consumed a probiotic in the two weeks prior to the study. 2. being under antibiotic treatment at the time of beginning the study. 3. being under pharmacological treatment for the treatment of candidiasis. 4. have an allergy to an antibiotic

Keywords: recurrent vulvovaginal candidiasis prevention probiotics
mhealth screening to prevent strokes

Conditions: Atrial Fibrillation

Summary: the purpose of this study is to investigate whether it is possible to identify a high-risk cohort suitable for screening for asymptomatic atrial fibrillation using claims data, and then engage those individuals in a mobile health technology-enabled home monitoring program in order to document previously undiagnosed atrial fibrillation, and provide clinical evidence of an outcomes benefit associated with this early detection.

the purpose of this study is to propose to study two different methods of intermittent rhythm monitoring in a cohort of individuals without prior history of atrial fibrillation, but determined to be at increased risk based on clinical risk factors, and compare the rate of atrial fibrillation detection through monitoring relative to routine care.

Eligibility criteria:
participants: the study population will be derived from the aetna and medicare populations. inclusion criteria: * male or females age \> 75 or * male age \> 55, or females age \> 65, and * prior cva, or * heart failure, or * diagnosis of both diabetes and hypertension, or * mitral valve disease, or * left ventricular hypertrophy, or * copd requiring home o2, or * sleep apnea, or * history of pulmonary embolism, or * history of myocardial infarction, or * diagnosis of obesity exclusion criteria: * current or prior diagnosis of atrial fibrillation, atrial flutter or atrial tachycardia * receiving chronic anticoagulation therapy * hospice care * end stage renal disease * diagnosis of moderate or greater dementia * implantable pacemaker and/or defibrillator * history of skin allergies to adhesive patches * known metastatic cancer * aetna compassionate care program (accp) participants - individuals with advanced illness and limited life expectancy

Keywords: atrial fibrillation wearable device wristband ecg patch strokes asymptomatic heart rhythm home monitoring
evaluation of the levels of pain, discomfort, and functional impairment with two techniques of retraction

Conditions: Class II Malocclusion

Summary: thirty-eight patients requiring extraction of maxillary first premolars will participate in the study. they will be divided randomly into two groups: an en-masse retraction group and a two-step group. in each group, anterior teeth retraction will be initiated after completion of the leveling and alignment phase via closed nickel-titanium coil springs applying 150 g of force per side, mini-implants will be used as an anchor unit in the en-masse retraction group, and tpa in the two-step's retraction group. the levels of pain, discomfort, and functional impairments will be self-reported using a validated questionnaire with a 4-points likert scale.

pain associated with orthodontic treatment is one of the undesirable complications, which negatively affects the patient's cooperation. pain may occur due to the pressure on the periodontal ligaments induced by orthodontic forces. the perception of pain is affected by many factors related to the patient, such as age, gender, and any previous treatment experiences, which are negatively or positively reflected in the patient's cooperation. as for the factors related to the type of orthodontic treatment provided. the levels of pain and discomfort vary with the different anchorage systems used during orthodontic treatment. several methods have been proposed to assure good anchorages, such as headgear, transpalatal arch (tpa) with or without a nance button, lingual arches, bonding of second molars, or intermaxillary elastics, and recently mini-implants. the use of mini-implants has recently become more common. the mini-implants have been used to secure absolute anchorage in en-mass retraction, canine retraction, total arch distalization, and anterior teeth intrusion. the most common usage is en-mass retraction of anterior teeth.

Eligibility criteria:
inclusion criteria: 1. adult healthy patients, male and female, age range: 17-27 years. 2. class ii division 1 malocclusion: * mild / moderate skeletal class ii (sagittal discrepancy angle 4\< anb\<10) * overjet more than 5 mm. * normal overbite (more than 0 mm and less than 4 mm) * normal or increased anterior facial height (clinically and then cephalometrically assessed using these three angles: mandibular/cranial base angle, maxillary/mandibular plane angle, and facial axis angle) * well-aligned maxillary teeth with minimal crowding (≤ 4 mm according to little's index), 3- complete permanent dentition (except for the third molars). 4- existence of all the upper teeth (except third molars). 5- good oral and periodontal health: * probing depth \< 4 mm * no radiographic evidence of bone loss. * gingival index ≤ 1 * plaque index ≤ 1 exclusion criteria: 1. medical conditions that affect tooth movement (corticosteroid, nonsteroidal anti-inflammatory drugs (nsaids), ...) 2. presence of primary teeth in the maxillary arch 3. any craniofacial syndromes. 4. poor oral hygiene or current periodontal disease: 5. the patient had previous orthodontic treatment
safe return to play after concussion

Conditions: Concussion, Brain; Sports Injury

Summary: this study will evaluate a combination of a novel dual-task regime together with other already known tests in terms of defining when an athlete is ready to return to play after a concussion.

in this prospective study, we will evaluate a combination of a novel facilitating agility dual-task regime together with sport concussion assessment tool -5 (scat5), vestibular/ocular-motor screening for concussion, agility t-test, joint repositions error test and pain catastrophizing scale (pcs) in terms of defining when an athlete is ready to return to play after a concussion. we will investigate if a novel facilitating agility dual-task test together with already widely used tests, can identify more athletes that after a concussion still isn't ready to return to play, due to a physiological deficit. we will test as many athletes as possible each season and when an athlete suffer a concussion, we will follow them to see when they reach their baseline level. as previous studies show a over representation of new injuries in athletes returning to play after a concussion, we will also register injuries from all included subjects in terms of injuries each year, to evaluate if athletes following our recommendations have a lower injury rate after returning to play after a concussion. we also hope to be able to get more knowledge about how pain catastrophizing is related to duration of concussions symptoms.

Eligibility criteria:
inclusion criteria: * athletes participating in sports at least 1xweek exclusion criteria: * injury that limits the participants ability to conduct the tests if the participant don't speak and understand danish or english other diseases or conditions that could interfere with one or more of the tests.

Keywords: return to play pain catastrophizing athletes
laryngeal cryotherapy for refractory neurogenic cough

Conditions: Upper-Airway Cough Syndrome

Summary: this study aims to evaluate the safety and efficacy of upper aerodigestive tract cryotherapy treatment in patients with refractory neurogenic cough in a prospective pilot study with a validated patient reported outcome measure

this study aims to test a new type of treatment for patients suffering from chronic cough, also known as upper airway cough syndrome. the new treatment involves the use of laryngeal cryotherapy which is the therapeutic freezing of tissue in the throat to numb the overactive sensory nerves in the throat which is believed to reduce cough symptoms. patients will first undergo a flexible scope of the throat (laryngoscopy) to test for hypersensitive areas in the throat, then undergo the cryotherapy procedure in the office. after that, patients will be followed up in the clinic with the usual standard of care visits and undergo validated cough surveys to track their cough symptoms after the procedure. possible side effects to this procedure are listed in detail below, and include temporary throat pain and coughing.

Eligibility criteria:
inclusion criteria: * adult patients 18 years or older with diagnosis of neurogenic cough * neurogenic cough is a diagnosis of exclusion applied to persistent cough (8 weeks or longer) * negative workup for other causes, including sinonasal allergies/chronic sinusitis, cough-variant asthma, and gerd * patient willing to participate in a clinical trial exclusion criteria: * uncontrolled reflux (scoring on reflux symptom index of 13 or higher) * vocal fold abnormalities or impairment * history of asthma or other underlying lung condition not adequately treated or controlled * uncontrolled allergic rhinitis (total nasal symptom score \>6, which would indicate moderate disease32) * reported symptom of postnasal drip * current smoker * current neuromodulator medication use * patient unwilling to participate in clinical trial or sign an informed consent * end stage medical disease with poor life expectancy * medical instability deemed by the investigators as a contraindication for enrollment * abnormal chest x-ray * abnormal pulmonary function testing (pfts) * positive local allergy panel (combined rast testing)
a study to assess the antibody response of healthy chinese children who have been vaccinated previously with 4-doses of prevenar (a pneumococcal vaccine) as babies and toddlers

Conditions: Pneumococcal Disease

Summary: in 2005, wyeth conducted study 0887x-101518 (nct00488826) in which chinese infants received either prevenar alone (group 1), prevenar given with a diphtheria, tetanus and acellular pertussis (dtap) vaccine (group 2) or dtap alone (group 3). this follow up study (at least 3 years after the last vaccination) will assess the antibody concentrations in children who previously completed wyeth study 0887x-101518.


Eligibility criteria:
inclusion criteria: * male or female subjects who participated in and completed wyeth study 0887x 101518. * healthy subject as determined by medical history, physical examination, and judgment of the investigator. exclusion criteria: * vaccination with any licensed or investigational pneumococcal vaccine since completion of wyeth study 0887x 101518. * history of culture proven invasive disease caused by s pneumoniae since the completion of wyeth study 0887x 101518. * known or suspected immune deficiency or suppression since participation in wyeth study 0887x 101518.

Keywords: vaccine prevenar pneumococcal disease
pain perception measurement by eeg and nrs

Conditions: Pain; Electroencephalography; Toothache

Summary: observational study at cdi cleveland dental institute. investigators will assess the pain perception in one group of patients using two non-invasive methods. first, a numerical rate scale (nrs) and second, a brain wave eeg.

to generate the nociceptive stimulus, the investigators will apply cold (endo-ice) to a healthy upper incisor tooth #8. inclusion criteria: patients between 20 and 60 years old, with healthy teeth, no history of dental alveolar trauma, and no pulp chamber calcification. after the nociceptive stimulus, patients will write their pain perception on paper from 0 to 10, and at the same time, we will record the brain activity with a non-invasive eeg emotiv. then, we will correlate both methods.

Eligibility criteria:
inclusion criteria: * males and females * age: 20-60 years. * tooth #8 vital and mature. no history of dentoalveolar trauma. * adequate coronal tooth structure. exclusion criteria: * chronic periodontitis. * vertical root fracture. * immature teeth. * necrotic teeth. * systemic diseases that affect the healing process. * non restorable teeth.

Keywords: pain perception numeric pain rating scale electroencephalography
non alcoholic fatty liver disease (nafld) in hong kong

Conditions: Fatty Liver

Summary: the true incidence and prevalence of nafld in hong kong has not been determined. the natural history of nafld is not well defined partly because of differences in the exclusion limit of alcohol and the required histological criteria between studies. nafld is previously believed to be a benign non-progressive condition, but it has since been determined that a subset of patients can progress to cirrhosis and even hepatocellular carcinoma. in fact in a recent histological review of nafld, fibrosis or liver cirrhosis was present in 15-50% of patients at index liver biopsy. the presence of obesity or type 2 diabetes mellitus are the strongest predictors of fibrosis. these same risk factors are also more common in patients with cryptogenic cirrhosis. further evidence of the link between diabetes, obesity and nafld are mainly from the field of liver transplantation. in patients who underwent liver transplantation for cryptogenic liver cirrhosis, nafld recuured in a quarter of the hepatic allografts. the patients with recurrent nafld were more likely to be diabetic and had a higher body mass index (bmi) at the time of recurrent nafld. this suggests that nafld may have a significant role in the pathogenesis of crytogenic cirrhosis. although nafld was initially described as a slowly progressive disease, there are emerging data which shows that it can progress rapidly. liver failure has even been described in patients with nafld after bariatric surgery, and a recent report described 5 cases of subacute liver failure in obese middle aged females with nafld related cirrhosis. nafld can also affect the progression of other diseases as well. hepatic steatosis related to visceral obesity is a major independent risk factor for fibrogenesis related to chronic hcv hepatitis. however, the prevalence of nafld and its interaction with chronic hbv, if any, is uncertain. this study aims to determine the prevalence of nafld in patients with unknown cause of hepatitis and to determine the histological fibrosis and inflammation in chronic hbv patients with nafld.


Eligibility criteria:
inclusion criteria: * 18-80 years old * gender: male and female exclusion criteria: * hbv patients and fatty liver hcv hiv

Keywords: nafld